Clinical trial · Interventional
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
A Phase II Study of Irinotecan and Taxotere With Concurrent Radiotherapy as a Preoperative Treatment in Resectable Esophageal Cancer
NCT00318903CI-TRIAL-00066700completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Esophagus | Malignant Esophageal Neoplasm | ALIAS | 0.90 |
| Cancer of the Esophagus | Malignant Esophageal Neoplasm | ALIAS | 0.90 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Esophageal Neoplasm | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Esophagus Cancer | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Esophagectomy (procedure) | Procedure | — | UNRESOLVED |
| Irinotecan (drug) | Drug | Irinotecan | ALIAS |
| Radiotherapy (procedure) | Procedure | — | UNRESOLVED |
| Taxotere (drug) | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Taxotere/Irinotecan
- description
- Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
- interventionNames
- Drug: Irinotecan (drug)
- Drug: Taxotere (drug)
- Procedure: Radiotherapy (procedure)
- Procedure: Esophagectomy (procedure)
Primary outcomes (1)
- measure
- The determination of pathologic response in patients who undergo surgical resection.
- timeFrame
- Approximately 14 weeks before eligible patients have surgery
Secondary outcomes (2)
- measure
- To assess the overall survival, time to treatment failure, and quality of life in patients who receive any therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Histological confirmation of adenocarcinoma/squamous cell carcinoma of the esophagus. Patients should be considered resection candidates, Clinical Stages II- IV (For GE junction tumors 50% of the tumor must be within the esophagus) * Age 19 years * Male or female gender (not pregnant or lactating). If the subject is fertile, use of medically acceptable contraception will be required, and women with reproductive potential shall have a negative pregnancy test. * Patient should be able to understand and offer signed written informed consent prior to study entry. * No prior receipt of surgery, chemotherapy, radiotherapy or immunotherapy. * Patients must demonstrate a ECOG P.S. ≤ 1 * Minimum life expectancy of 12 weeks * End Organ function must be adequate meeting the below criteria at baseline: WBC 3000/mm3, ANC 1500/mm3 , Hgb 9.0 g/dL, PLT 100,000mm3 Normal serum creatinine ( 1.5 mg/dL) Total Bilirubin ULN, Transaminases (SGOT and/or SGPT) may be up to 1.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is \< ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are \< ULN. PT/PTT below the upper limit of normal (patients may be on 1mg of Coumadin for line patency) Peripheral neuropathy must be \< Grade 1 Exclusion Criteria: * Diagnosis of active, invasive (treated in past 5 years) concomitant malignancy except non-melanotic skin cancer * Patients must be fully recovered from any reversible side effects of prior intervention * Presence of an underlying disease state associated with impairment of performance status * New York Heart Association Class IV congestive heart failure * Limited mental capacity or language skills to the extent simple instructions cannot be followed or information regarding adverse events cannot be provided History of non-compliance with prescribed medical care. * Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80 must be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.